Page 36 - Personalised medicine of fluoropyrimidines using DPYD pharmacogenetics Carin Lunenburg

Chapter 2
Pharmacogenetics. 1998;8(6):455-459.
19. Toffoli G, Giodini L, Buonadonna A, et al. Clinical validity of a DPYD-based pharmacogenetic test
to predict severe toxicity to fluoropyrimidines. Int J Cancer. 2015;137(12):2971-2980.
20. Offer SM, Fossum CC, Wegner NJ, Stuflesser AJ, Butterfield GL, Diasio RB. Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase
activity. Cancer Res. 2014;74(9):2545-2554.
21. Morel A, Boisdron-Celle M, Fey L, et al. Clinical relevance of different dihydropyrimidine
dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol Cancer
Ther. 2006;5(11):2895-2904.
22. Mercier C, Ciccolini J. Profiling dihydropyrimidine dehydrogenase deficiency in patients with
cancer undergoing 5-fluorouracil/capecitabine therapy. Clin Colorectal Cancer. 2006;6(4):288-
296.
23. Hsiao H-H, Lin S-F. Pharmacogenetic syndrome of dihydropyrimidine dehydrogenase deficiency.
Current Pharmacogenomics. 2007;5(1):31-38.
24. Ezzeldin H, Diasio R. Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome
associated with potentially life-threatening toxicity following 5-fluorouracil administration. Clin
Colorectal Cancer. 2004;4(3):181-189.
25. Raida M, Schwabe W, Hausler P, et al. Prevalence of a common point mutation in the
Dihydropyrimidine dehydrogenase (DPD) gene within the 5 ‘-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls. Clinical Cancer Research. 2001;7(9):2832-2839.
26. Swen JJ, Huizinga TW, Gelderblom H, et al. Translating pharmacogenomics: challenges on the road to the clinic. PLoS Med. 2007;4(8):e209.
27. Ciccolini J. Integrating Pharmacogenetics testing at the bedside: Yes we can! Drug Metabol Drug Interact. 2013;Conference: 2nd ESPT Conference “Pharmacogenomics: From Cell to Clinic” Lisbon Portugal.(var.pagings):A12.
28. Goldstein DA, Shaib WL, Flowers CR. Costs and effectiveness of genomic testing in the management of colorectal cancer. Oncology (Williston Park). 2015;29(3):175-183.
29. van Staveren MC, Guchelaar HJ, van Kuilenburg ABP, Gelderblom H, Maring JG. Evaluation of predictive tests for screening for dihydropyrimidine dehydrogenase deficiency. Pharmacogenomics J. 2013;13(5):389-395.
30. Meulendijks D, Henricks LM, Sonke GS, et al. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 2015;16(16):1639- 1650.
31. Joerger M, Huitema AD, Boot H, et al. Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy. Cancer Chemother Pharmacol. 2015;75(4):763-772.
32. Falvella FS, Cheli S, Martinetti A, et al. DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan. Br J Clin Pharmacol. 2015.
33. Yu W, Janssens C, Gwinn M, Khoury MJ. HuGE Risk Translator. HuGE Navigator (version 2.0). 2010; http://www.hugenavigator.net/HuGENavigator/checkerComplexStartPage.do. Accessed
34